Clinical Trial Update: Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

View source ↗

Summary

A completed real-world chart review study describing the clinical profile of idiopathic pulmonary fibrosis patients treated with nintedanib (OFEV) in Spain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED | Results posted: 2019-08-01